Search results for "HCV"

showing 10 items of 277 documents

Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment.

2013

SummaryLiver fibrosis results from an excessive wound healing response in most chronic liver diseases, such as hepatitis C. Despite great advances in antiviral therapy in recent years, progressive liver fibrosis remains a major problem for patients with recurrent hepatitis C after liver transplantation. Liver biopsy remains a central tool in the management of HCV-positive liver transplant recipients, but reliable non-invasive methods for the assessment of liver fibrosis, such as ultrasound elastography, are increasingly being incorporated in the management of post-transplant patients, helping predict prognosis, guide treatment decisions, and stratify patients for emerging antifibrotic thera…

Liver Cirrhosismedicine.medical_specialtyCirrhosisMacrophagemedicine.medical_treatmentBiopsyLiver transplantationGastroenterologyAntiviral AgentsPost-transplantFibrosisRecurrenceNAFLDInternal medicineMedicineHumansHepatic stellate cellSerum markerHepatitisTransplantationProgressionHepatologymedicine.diagnostic_testbusiness.industryT cellSecond hitHepatitis Cmedicine.diseasePrognosisFibrosisHepatitis CLiver TransplantationTransplantationCirrhosisLiverTGFbetaLiver biopsyHCVHepatic stellate cellDisease ProgressionInterferonElasticity Imaging TechniquesCollagenAntifibroticElastographybusinessJournal of hepatology
researchProduct

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospecti…

2008

SUMMARY Pegylated interferon with ribavirin (Peg/R) is the most effective therapy for chronic hepatitis C virus (HCV) but its utility and effectiveness after liver transplantation has been difficult to assess. We evaluated efficacy, tolerability, and safety of Peg/R in liver transplant candidates and recipients with HCV cirrhosis. We searched medical databases and conference proceedings between January 1999 and January 2008 selecting randomized and nonrandomized studies. Primary end points meta-analytically were: (1) sustained viral response (SVR) and (2) histological response. Secondary end points were: (1) treatment discontinuation, (2) mortality, and (3) rejection episodes. Pegylated int…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentHepacivirusPharmacologyLiver transplantationAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesRandomized Controlled Trials as TopicClinical Trials as Topiccirrhosis HCV pegylated interferon ribavirin transplantation.Hepatologybusiness.industryRibavirinvirus diseasesmedicine.diseaseHepatitis CLiver TransplantationDiscontinuationTransplantationRegimenTreatment OutcomeInfectious DiseaseschemistryTolerabilityDrug Therapy CombinationInterferonsbusinessmedicine.drug
researchProduct

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.

2008

OBJECTIVES: Metabolic factors may affect the course of chronic hepatitis C (CHC). Insulin resistance (IR) determines steatosis, but its direct role in affecting progression of hepatic fibrosis is less clear. We aimed to assess whether increasing degrees of IR, up to overt diabetes, are linked to steatosis and higher stages of fibrosis in patients with CHC resulting from genotype 1 HCV (G1-HCV). METHODS: Two hundred one consecutive patients with G1-HCV infection were evaluated by liver biopsy and anthropometric and metabolic measurements, including IR, by the homeostasis model assessment (HOMA). Nondiabetic patients were defined as insulin resistant if HOMA-IR was >2.7. All biopsies were …

Liver Cirrhosismedicine.medical_specialtyGenotypeBiopsyHepacivirusSettore MED/08 - Anatomia PatologicaGastroenterologyCohort StudiesInsulin resistanceLiver Function TestsFibrosisRisk FactorsInternal medicineDiabetes mellitusGenotypeBiopsymedicineHumansSettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyvirus diseasesHepatitis CHepatitis C Chronicmedicine.diseasePrognosisdigestive system diseasesFatty LiverEndocrinologyCross-Sectional StudiesDiabetes Mellitus Type 2Liverhcv fibrosis IR liverRNA ViralViral diseaseInsulin ResistancebusinessLiver function testsThe American journal of gastroenterology
researchProduct

Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group

2019

Abstract Hepatitis C virus (HCV) remains a significant public health problem and is one of the major causes of chronic liver disease worldwide. In recent years many new tools to facilitate widespread HCV screening and new therapeutic options with excellent efficacy and tolerability profiles and cost lowering policies have become available. To fully utilise these new tools, the link between local and specialist centres for the management of HCV infection must be reinforced. In order to GAIN further insight into these aspects, with a particular focus on the Italian scenario, a group of experts met to discuss relevant aspects and open issues on chronic HCV. As a summary of that meeting, the fo…

Liver Cirrhosismedicine.medical_specialtyHepatitis C virusHepacivirusChronic liver diseasemedicine.disease_causeAntiviral Agents03 medical and health sciences0302 clinical medicineLinkage to careHumansMass ScreeningMedicineEradication; Hepatitis C virus; Linkage to careIntensive care medicineSocieties MedicalEradicationHepatologybusiness.industryHepatitis C virusAdvanced cirrhosisPublic healthManaged Care ProgramsGastroenterologyvirus diseasesFocus Groupsmedicine.diseaseHepatitis CFocus groupdigestive system diseasesItalyTolerability030220 oncology & carcinogenesisHCV030211 gastroenterology & hepatologybusinessHepatitis C viruHealthcare providers
researchProduct

Prevalence and risk factors for advanced liver fibrosis in HIV/HCV-coinfected individuals

2010

Liver fibrosis HIV HCV coinfection transient elastography
researchProduct

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

2018

AbstractNatural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort of patients infected with the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed in 1445 HCV-infected DAA-naïve patients. Sanger-sequencing was performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a and 99 GT4d samples. Overall, 20.7% (301/1455) of patients showed natural RASs, and the prevalence of multiclass-resistance was 7.3% (29/372 patients analysed). NS3-RASs were particularly common in GT1a and GT1b (45.2-10.8%, respectively), mai…

Male0301 basic medicineSofosbuvirHepacivirusDrug Resistancelcsh:MedicineHepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyHepatitis C Virus; HCV resistance-testchemistry.chemical_compound0302 clinical medicineGenotypePrevalenceVirallcsh:ScienceHCV resistance-testMultidisciplinarybiologyHepatitis CMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCohortHCVFemale030211 gastroenterology & hepatologymedicine.drugAdultmedicine.medical_specialtyHepatitis C VirusGenotypeHCV RASHepatitis C virus03 medical and health sciencesInternal medicineDrug Resistance ViralmedicineHumansAdult; Aged; Drug Resistance Viral; Female; Hepacivirus; Hepatitis C; Humans; Italy; Male; Middle Aged; Prevalence; Viral Nonstructural Proteins; GenotypeNS5ANS5BAgedbusiness.industrylcsh:RHepatitis C Virus HCV resistance-testbiology.organism_classificationmedicine.disease030104 developmental biologychemistrylcsh:Qbusiness
researchProduct

Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

2019

Background & Aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation. Methods: We prospectively enrolled 163 consecutive patients with HCV-related cirrhosis and a first diagnosis of early Barcelona Clinic Liver Cancer stage 0/A HCC, who had achieved a complete radiologic response after curative resection or ablation and were subsequently treated with DAA…

Male0301 basic medicinemedicine.medical_specialtySurvival rateCarcinoma HepatocellularCirrhosisSustained Virologic ResponsePrognosiHepatitis C virus (HCV) Hepatocellular carcinoma (HCC) Direct-acting antiviral (DAA) Overall survival Prognosis Survival rate Liver cirrhosisHepacivirusAntiviral AgentsGastroenterologyLiver cirrhosi03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansEarly Hepatocellular CarcinomaOverall survivalProspective StudiesHepatocellular carcinoma (HCC)Propensity ScoreSurvival rateAgedAged 80 and overHepatologybusiness.industryLiver NeoplasmsHazard ratioDirect-acting antiviral (DAA)Hepatitis CHepatitis C virus (HCV)Middle Agedmedicine.diseasePrognosisHepatitis CDirect-acting antiviral (DAA); Hepatitis C virus (HCV); Hepatocellular carcinoma (HCC); Liver cirrhosis; Overall survival; Prognosis; Survival rate030104 developmental biologyHepatocellular carcinomaLiver cirrhosisFemale030211 gastroenterology & hepatologyNeoplasm Recurrence LocalLiver cancerbusinessViral hepatitisFollow-Up Studies
researchProduct

NS5A gene analysis by next generation sequencing in HCV nosocomial transmission clusters of HCV genotype 1b infected patients

2019

Background: The aim of the study was to investigate the intra-host variability through next-generation-sequencing (NGS) of the NS5A-gene in nosocomial transmission-clusters observed in two Italian hospitals among hepatitis C virus (HCV)-genotype-1b infected patients. Methods: HCV-sequencing was performed by Sanger-sequencing (NS3 + NS5A + NS5B) and by NGS (NS5A, MiSeq-Illumina) in 15 HCV-1b infected patients [five acute with onco-hematologic-disease and 10 (4/6 acute/chronic) with &beta

Male0301 basic medicinevirusesDrug ResistanceHepacivirusViral Nonstructural Proteinsmedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataGastroenterologySettore MED/07chemistry.chemical_compound0302 clinical medicineGenotype 1bMedicineVirallcsh:QH301-705.5PhylogenyCross Infectionnosocomial transmissionGastroenterologyHigh-Throughput Nucleotide Sequencingvirus diseasesHCV; NGS; acute infection; chronic infection; nosocomial transmission; sequencing; Acute Disease; Adult; Amino Acid Substitution; Antiviral Agents; Blood Transfusion; Chronic Disease; Cross Infection; Drug Resistance Viral; Female; Genotype; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Host-Pathogen Interactions; Humans; Interferons; Male; Middle Aged; Phylogeny; Polymorphism Single Nucleotide; Viral Nonstructural Proteins; beta-ThalassemiaSingle NucleotideGeneral MedicinesequencingMiddle AgedHepatitis CNGSAcute DiseaseHost-Pathogen InteractionsHCVFemale030211 gastroenterology & hepatologyAdultmedicine.medical_specialtyGenotypeHepatitis C virusViral quasispeciesPolymorphism Single NucleotideAntiviral AgentsArticleDNA sequencing03 medical and health sciencesInternal medicineDrug Resistance ViralHumansBlood TransfusionPolymorphismNS5ANS5BGeneHepatologybusiness.industryNosocomial transmissionbeta-Thalassemiabiochemical phenomena metabolism and nutritionchronic infectionVirologydigestive system diseasesChronic infection030104 developmental biologyAmino Acid Substitutionchemistrylcsh:Biology (General)Chronic DiseaseHCV; NGS; acute infection; chronic infection; nosocomial transmission; sequencingInterferonsbusinessacute infectionDigestive and Liver Disease
researchProduct

Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?

2019

AbstractBackgroundAlcohol consumption is a known risk factor for liver disease in HIV-infected populations. Therefore, knowledge of alcohol consumption behaviour and risk of disease progression associated with hazardous drinking are important in the overall management of HIV disease. We aimed at assessing the usefulness of routine data collected on alcohol consumption in predicting risk of severe liver disease (SLD) among people living with HIV (PLWHIV) with or without hepatitis C infection seen for routine clinical care in Italy.MethodsWe included PLWHIV from two observational cohorts in Italy (ICONA and HepaICONA). Alcohol consumption was assessed by physician interview and categorized ac…

Male030508 substance abuseHIV InfectionsSeverity of Illness IndexCohort StudiesLiver disease0302 clinical medicineRisk FactorsEpidemiologyMedicineHIV InfectionAlcohol consumptionAlcohol consumption HIV-infected HIV/HCV co-infection Severe liver disease030212 general & internal medicineeducation.field_of_studyCoinfectionLiver Diseaselcsh:Public aspects of medicineLiver DiseasesHazard ratioHepatitis CMiddle AgedHepatitis CItalyalcohol consumption; HIV-infected; HIV/HCV co-infection; severe liver diseaseCoinfectionFemale0305 other medical scienceHumanCohort studyResearch ArticleAdultmedicine.medical_specialtyAlcohol DrinkingPopulationSevere liver diseaseHIV/HCV co-infectionNO03 medical and health sciencesEnvironmental healthHumansRisk factorAlcohol consumption; HIV-infected; HIV/HCV co-infection; Severe liver disease; Adult; Alcohol Drinking; Cohort Studies; Female; HIV Infections; Hepatitis C; Humans; Italy; Liver Diseases; Male; Middle Aged; Risk Factors; Severity of Illness Index; CoinfectioneducationHIV-infectedbusiness.industryRisk FactorPublic Health Environmental and Occupational Healthlcsh:RA1-1270medicine.diseaseCohort StudiebusinessBMC Public Health
researchProduct

Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational…

2021

Abstract Background and Aims The MARS post-marketing, observational study evaluates glecaprevir/pibrentasvir in a large population of Italian patients who are infected with HCV. Patients and Methods Achievement of SVR12 was the primary endpoint in the overall population and by subpopulations of interest (treatment-naive and treatment-experienced patients, subjects infected with different HCV genotype/sub-genotype, cirrhotic and non-cirrhotic patients, patients with different severity of fibrosis, patients with an APRI score ≥1, subjects with comorbidities, HIV-coinfected patients, elderly patients and people who use drugs). Safety and quality of life (assessed by SF-36 and Work Productivity…

MaleAdultmedicine.medical_specialtyPyrrolidinesQuinoxalineSustained Virologic ResponseSettore MED/12 - GASTROENTEROLOGIAPopulationAntiviral AgentselderlyBenzimidazoleGLE/PIBQuinoxalinesInternal medicineDrug CombinationClinical endpointmedicineProduct Surveillance PostmarketingHumansProspective StudieseducationAdverse effectAgedAntiviral AgentSulfonamideseducation.field_of_studyHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAGastroenterologyPWUDGlecaprevirMiddle Agedelderly; GLE/PIB; HCV; PWUDHepatitis C ChronicPibrentasvirDiscontinuationDrug CombinationsGLE/PIB; HCV; PWUD; elderlyItalyCohortHCVQuality of LifeBenzimidazolesFemaleObservational studybusiness
researchProduct